ClinicalTrials.gg
CompletedNCT00553358Neo ALTTOUpdated Sep 21, 2021Results posted

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 122 sites in 24 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know · 9 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
8th of 114
455 · median 35
Started
2008
with 14 others
Phase 3
18 of 114
none open now
Registered
48th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 15 that started in 2008, is one of 18 in phase 3, and was the 48th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This is a randomised, open label multicenter Phase III study comparing the efficacy of neoadjuvant lapatinib plus paclitaxel, versus trastuzumab plus paclitaxel, versus concomitant lapatinib and trastuzumab plus paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer.

Patients will be randomised to receive either: lapatinib 1500 mg daily, trastuzumab 4 mg/kg intravenous (IV) load followed by 2 mg/kg IV weekly, or lapatinib 1000 mg daily with trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV weekly for a total of 6 weeks. After this biological window, patients on monotherapy arms will continue on the same targeted therapy plus weekly paclitaxel 80 mg/m\^2 for a further 12 weeks, up to definitive surgery. In the combination arm, patients will receive lapatinib 750 mg daily in combination with trastuzumab 2 mg/kg IV plus weekly paclitaxel 80mg/m\^2 IV for a further 12 weeks, up to definitive surgery. After surgery, patients will receive three courses of adjuvant chemotherapy with 5-Fluorouracil Epirubicin Cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant setting for a further 34 weeks (in the combination arm, lapatinib dose will be 1000 mg daily in combination with trastuzumab). The planned total duration of the anti-HER2 therapy one year.

Primary objective is to evaluate and compare the rate of pathological complete response (pCR) at the time of surgery in patients with HER2/ErbB2 overexpressing or amplified operable breast cancer randomised to lapatinib followed by lapatinib plus paclitaxel versus trastuzumab followed by trastuzumab plus paclitaxel versus lapatinib in combination with trastuzumab followed by lapatinib, trastuzumab plus paclitaxel.

Read the detailed description

This was a parallel group, three-arm, randomized, multicenter, open-label phase III study. The study compared the efficacy and tolerability of neoadjuvant lapatinib and paclitaxel, versus trastuzumab and paclitaxel, versus the combination of lapatinib with trastuzumab and paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer. Subjects were randomized to receive lapatinib, trastuzumab or lapatinib plus trastuzumab for a total of 6 weeks. After this biological window, subjects continued on the same targeted therapy plus weekly paclitaxel for a further 12 weeks, until definitive surgery (total neoadjuvant therapy duration of 18 weeks). Paclitaxel could be initiated at Week 4 if there is evidence of progressive disease (PD) at that time. Within 6 weeks after surgery, subjects received 3 cycles of adjuvant 5-flourouracil, epirubicin and cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant phase for a further 34 weeks (to complete 52 weeks of anti-HER2 therapy).

After completing 52 weeks of (neo-)/adjuvant anti-HER2 therapy, subjects were scheduled to attend post-treatment follow-up every 3 months during the first year (months 12, 15, 18, 21, and 24), every 6months in Years 3 to 5 inclusive, and annually thereafter up to Year 10. Each subject was to be followed for 10 Years. All subjects were to be followed for EFS and OS up to 10 years from last subject randomized.

03

Conditions studied

  • Neoplasms, Breast

Keywords

  • Lapatinib
  • ErbB2+
  • Early Breast Cancer
  • Neoadjuvant
  • breast carcinoma
  • breast cancer
  • breast lump
  • HER2 positive metastatic breast cancer
  • breast cancer positive for human epidermal growth factor receptor 2 (HER2) HER2 positive metastatic breast cancer
  • breast cancer progression
  • estrogen-receptor (ER) positive(+) breast cancer
  • Paget's disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female gender;
  • Age ≥18 years;
  • Performance Status- (ECOG) 0-1
  • confirmed invasive breast cancer:
  • Primary tumour greater than 2 cm diameter, measured by clinical examination and mammography or echography,
  • Any N,
  • No evidence of (M0) (isolated supraclavicular node involvement allowed);
  • Over expression and/or amplification of in the invasive component of the primary tumour [Wolff et al 2006] and confirmed by a certified laboratory prior to randomisation
  • Known hormone receptor status.
  • Haematopoietic status:
  • ≥ 1,5 x 10\^9/L,
  • count ≥ 100 x 10\^9/L,
  • at least 9 g/dl,
  • Hepatic status:
  • Serum total ≤ 1.5 x (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 2 x ULN) is allowed,
  • (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times ULN,
  • Alkaline phosphatase ≤ 2.5 times ULN,
  • Renal status:
  • Creatinine ≤ 2.0 mg/dL,
  • Cardiovascular:
  • Baseline (LVEF) ³ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,
  • Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization (For women of )
  • Fertile patients must use effective (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed)
  • Signed form (ICF)
  • Patient accepts to make available tumour samples for submission to central laboratory to conduct translational studies as part of this protocol

Exclusion criteria

Exclusion Criteria:

  • Received any prior treatment for primary invasive breast cancer;
  • Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated:
  • Basal and squamous cell carcinoma of the skin;
  • Carcinoma in situ of the cervix.
  • Patients with a prior diagnosed more than 10 years prior to randomisation may enter the study. Patients must have been curatively treated with surgery alone. Radiation therapy or systemic therapy (chemotherapy or endocrine) are NOT permitted. Prior diagnoses of breast cancer or melanoma are excluded.
  • Diagnosis of inflammatory breast cancer;
  • Bilateral cancer;
  • This criterion has been deleted from the protocol Version 1. Patients with multi-focal cancer are no longer excluded.
  • Known history of uncontrolled or symptomatic angina, arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen;
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;
  • Unresolved or unstable, serious adverse events from prior administration of another drug;
  • Active or uncontrolled infection;
  • Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;
  • Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies);
  • Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to trastuzumab or lapatinib or their ;
  • Pregnant or lactating women;
  • Concomitant use of inhibitors or inducers
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
455 participants (actual)

Study arms

  • Experimental
    Arm 1 Lapatinib

    1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.

    Drug: Lapatinib · Drug: Paclitaxel

  • Active comparator
    Arm 2 Trastuzumab

    4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).

    Biological: Trastuzumab · Drug: Paclitaxel

  • Experimental
    Arm 3 Lapatinib plus Trastuzumab

    1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).

    Drug: Lapatinib · Biological: Trastuzumab · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery

    Pathological complete response is defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen. Surgical breast and axillary node resection specimens were evaluated for pathologic tumor response according to National Surgical Adjuvant Breast and Bowel Project (NSABP) guidelines, which do not take into account the histological nodal status.

    Time frame: Weeks 20 to 22

Secondary outcomes

  1. Number of Participants With Overall Response at Week 6

    The number of participants with overall response (complete response and/or partial response) was evaluated using World Health Organization (WHO) criteria by clinical examination and by mammography and breast echography with bi-dimensional measurements at Week 6. As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.

    Time frame: Week 6

  2. Overall Response at the Time of Surgery

    The number of participants with overall response (complete response and/or partial response) was evaluated using WHO criteria by clinical examination and mammography and breast echography with bi-dimensional measurements at the time of surgery (Weeks 20 to 22). As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.

    Time frame: Time of surgery (Weeks 20 to 22)

  3. Number of Participants With Negative Lymph Nodes at the Time of Surgery

    Participants were assessed for node-negative lymph nodes at the time of surgery. As per the pathological TNM (Tumor, Node, Metastases) classification (pTNM) of malignant tumors: pN, absence or presence and extent of regional lymph node metastasis. Node-negative (pN0) participants had no regional lymph node metastasis. Although not assessed in this measure, pT is the extent of primary tumor, and pM is the absence or presence of distant metastasis.

    Time frame: Time of surgery (Weeks 20 to 22)

  4. Number of Participants With Actual Indicated Surgery

    Participants were assessed for the type of surgery they underwent for breast cancer. Non-conservative surgery is defined as a radical or modified radical mastectomy. Conservative surgery is comprised of a lumpectomy, a quadrantectomy/segmentectomy, or a partial mastectomy. Participants who were not assessed as being candidates for non-conservative or conservative surgery were classified as non-operable.

    Time frame: At surgery (Weeks 20 to 22)

  5. Mean Change From Baseline in Tumor Size at Week 6 and at Surgery

    Mean change from baseline in tumor in tumor size. Change from baseline in tumor size was defined as tumor size at Week 6/ surgery (Weeks 20 to 22) minus tumor size at baseline. The difference in treatment arms was estimated for Lapatinib 1500 mg versus Trastuzumab 2 mg/kg and for Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg versus Trastuzumab 2 mg/kg.

    Time frame: Week 6 and surgery (Weeks 20 to 22)

  6. Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab

    Participants with progressive disease at 4 week assessment that were permitted to commence treatment with paclitaxel.

    Time frame: Week 6

  7. Event-free Survival (EFS) - Median Clinical Follow-up

    Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.

    Time frame: From randomization up to approximately year 10

  8. Event-free Survival (EFS) - Events and Censoring

    Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.

    Time frame: From randomization up to approximately year 10

  9. Overall Survival (OS) - Median Survival Follow-up

    Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.

    Time frame: From randomization up to approximately year 10

  10. Overall Survival (OS) - Deaths and Censoring

    Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.

    Time frame: From randomization up to approximately year 10

  11. Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)

    The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Clinical follow-up is the period during which the patient is monitored such that all recurrence or second primary malignancy (SPM) or contralateral breast cancer (CBC) events would be reported. Patients are considered in clinical follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death.

    Time frame: up to year 10

  12. Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)

    The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. For patients who had breast cancer surgery, EFS events are post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For patients who do not undergo breast cancer surgery, EFS events are death during clinical follow-up or non-completion of any neo-adjuvant investigational product due to disease progression or second primary malignancy or contralateral breast cancer.

    Time frame: up to year 10

  13. Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)

    The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Patients are considered in survival follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death. For subjects with no death recorded in the database, time to death is censored.

    Time frame: up to year 10

  14. Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)

    The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Includes deaths due to any cause.

    Time frame: up to year 10

  15. To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints

    Time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 31 weeks.

  16. Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)

    Metabolic Response Rate determined by Positron Emission Tomography/Computed Tomography (PET/CT)

    Time frame: Week 2 and Week 6

  17. Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.

    Biomarker levels of phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) were assessed in participants at baseline.

    Time frame: Baseline

  18. Percentage of Participants With the Indicated Biomarker Expression - PTEN.

    Biomarker levels of phosphate and tensin homolog deleted from chromosome 10 (PTEN) were assessed in participants at baseline.

    Time frame: Baseline

  19. Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR

    Ratio (95% CI) of geometric means in p95 human epidermal growth factor receptor (p95HER2) expression in hormone-receptor (HR) positive patients with pathological complete response (pCR) vs no pCR

    Time frame: Baseline

  20. Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream

    Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. In the adjuvant phase, after surgery all participants received 3 courses of adjuvant 5-fluorouracil, epirubicin and cyclophosphamide, followed by lapatinib 1500 mg or trastuzumab 2 mg/kg or lapatinib 1000/750 mg plus trastuzumab 2 mg/kg given prior to surgery in the neoadjuvant setting for an additional 34 weeks.

    Time frame: Measurement performed at one or more of the time points: baseline, week 2 or week 18

07

Results

Posted Oct 13, 2011

Participant flow

Participant flow — Overall Study
MilestoneLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
Started152154149
Completed735861
Not completed799688
Withdrew: Randomized but did not receive treatment331
Withdrew: Lost to follow-up222618
Withdrew: Withdrew completely233334
Withdrew: Died during clinical follow-up252932
Withdrew: Not dead but were last followed-up prior to 9 years + 6 months after randomization422
Withdrew: Died after clinical follow-up ended120
Withdrew: Withdrew (survival only) - alive at end of survival follow-up111

Outcome measures

PrimaryNumber of Participants With Pathological Complete Response (pCR) at the Time of Surgery

Pathological complete response is defined as no invasive cancer in the breast or only non-invasive in situ cancer in the breast specimen. Surgical breast and axillary node resection specimens were evaluated for pathologic tumor response according to National Surgical Adjuvant Breast and Bowel Project (NSABP) guidelines, which do not take into account the histological nodal status.

Time frame:
Weeks 20 to 22
Reported as:
Number · participants
Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery384478
Statistical analysis
  • Lapatinib 1500 mg vs Trastuzumab 2 mg/kg · Binomial · p = 0.3416 · Percentage of participants with pcr: -4.85 · 97.5% CI -17.6 to 8.16Estimation Comments: Estimated value is the difference in the percentage of participants with pCR: Arm1 (Lapatinib 1500 mg) minus Arm2 (Trastuzumab 2 mg/kg).
  • Trastuzumab 2 mg/kg vs Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg · Binomial · p = 0.0001 · Percentage of participants with pcr: 21.79 · 97.5% CI 9.08 to 34.23Estimation Comments: Estimated value is the difference in the percentage of participants with pCR: Arm3 (Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg) minus Arm2 (Trastuzumab 2 mg/kg)
SecondaryNumber of Participants With Overall Response at Week 6

The number of participants with overall response (complete response and/or partial response) was evaluated using World Health Organization (WHO) criteria by clinical examination and by mammography and breast echography with bi-dimensional measurements at Week 6. As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.

Time frame:
Week 6
Reported as:
Number · participants
Number of Participants With Overall Response at Week 6
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Overall Response8145102
No Change578133
Progressive Disease5112
Not Evaluated7912
Missing Data433
SecondaryOverall Response at the Time of Surgery

The number of participants with overall response (complete response and/or partial response) was evaluated using WHO criteria by clinical examination and mammography and breast echography with bi-dimensional measurements at the time of surgery (Weeks 20 to 22). As per WHO criteria: complete response is defined as the disappearance of all lesions; partial response is defined as a greater than 50% decrease in the sum of products of the greatest length and width of the largest lesion; progressive disease is defined as a greater than 25% increase in the sum of products of all measurable lesions.

Time frame:
Time of surgery (Weeks 20 to 22)
Reported as:
Number · participants
Overall Response at the Time of Surgery
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Overall Response114105122
No Change8167
Progressive Disease021
Not Evaluated192014
Missing Data1368
SecondaryNumber of Participants With Negative Lymph Nodes at the Time of Surgery

Participants were assessed for node-negative lymph nodes at the time of surgery. As per the pathological TNM (Tumor, Node, Metastases) classification (pTNM) of malignant tumors: pN, absence or presence and extent of regional lymph node metastasis. Node-negative (pN0) participants had no regional lymph node metastasis. Although not assessed in this measure, pT is the extent of primary tumor, and pM is the absence or presence of distant metastasis.

Time frame:
Time of surgery (Weeks 20 to 22)
Reported as:
Number · participants
Number of Participants With Negative Lymph Nodes at the Time of Surgery
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Number of Participants With Negative Lymph Nodes at the Time of Surgery7282100
SecondaryNumber of Participants With Actual Indicated Surgery

Participants were assessed for the type of surgery they underwent for breast cancer. Non-conservative surgery is defined as a radical or modified radical mastectomy. Conservative surgery is comprised of a lumpectomy, a quadrantectomy/segmentectomy, or a partial mastectomy. Participants who were not assessed as being candidates for non-conservative or conservative surgery were classified as non-operable.

Time frame:
At surgery (Weeks 20 to 22)
Reported as:
Number · participants
Number of Participants With Actual Indicated Surgery
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Conservative665863
Non-conservative778580
Non-operable1169
SecondaryMean Change From Baseline in Tumor Size at Week 6 and at Surgery

Mean change from baseline in tumor in tumor size. Change from baseline in tumor size was defined as tumor size at Week 6/ surgery (Weeks 20 to 22) minus tumor size at baseline. The difference in treatment arms was estimated for Lapatinib 1500 mg versus Trastuzumab 2 mg/kg and for Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg versus Trastuzumab 2 mg/kg.

Time frame:
Week 6 and surgery (Weeks 20 to 22)
Reported as:
Mean · millimeters
Mean Change From Baseline in Tumor Size at Week 6 and at Surgery
millimetersLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Week 6-20.45 ± 18.43-13.42 ± 16.44-25.77 ± 19.91
Surgery (Weeks 20 to 22)-41.01 ± 23.81-35.47 ± 22.95-43.59 ± 26.88
SecondaryNumber of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab

Participants with progressive disease at 4 week assessment that were permitted to commence treatment with paclitaxel.

Time frame:
Week 6
Reported as:
Number · participants
Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab
participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab8126
SecondaryEvent-free Survival (EFS) - Median Clinical Follow-up

Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.

Time frame:
From randomization up to approximately year 10
Reported as:
Median · years
Event-free Survival (EFS) - Median Clinical Follow-up
yearsLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
Event-free Survival (EFS) - Median Clinical Follow-up9.69 (9.55 to 9.73)9.60 (8.21 to 9.69)9.66 (9.50 to 9.72)
SecondaryEvent-free Survival (EFS) - Events and Censoring

Event free survival (EFS) is defined as the time from randomization to first EFS event. For subjects who had breast cancer surgery, EFS events were post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For subjects who did not have breast cancer surgery, EFS events were death during clinical follow-up or non-completion of any neoadjuvant investigational product due to disease progression.

Time frame:
From randomization up to approximately year 10
Reported as:
Number · Number of Participants
Event-free Survival (EFS) - Events and Censoring
Number of ParticipantsLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
Number of subjects with EFS events434747
Number of subjects censored - total109107102
Number of subjects censored - Clinical follow-up ongoing000
Number of subjects censored - Clinical follow-up ended - total10310599
Number of subjects censored -Clinical follow-up ended - Completed study follow-up614958
Number of subjects censored - Clinical follow-up ended - Lost to follow-up172010
Number of subjects censored - Clinical follow-up ended - Withdrew (but consent for survival f/u)364
Number of subjects censored - Clinical follow-up ended - Withdrew223027
Number of subjects censored - Other623
Statistical analysis
  • Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg vs Trastuzumab 2 mg/kg · Regression, Cox · p = 0.548 (The two-sided stratified log-rank test was implemented as the score test from the Cox model.) · Hazard ratio (hr): 0.878 · 95% CI 0.57 to 1.34Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate hazard ratios and corresponding confidence intervals for the pairwise comparisons of individual treatment arms with the trastuzumab alone arm.
  • Lapatinib 1500 mg vs Trastuzumab 2 mg/kg · Regression, Cox · p = 0.981 (The two-sided stratified log-rank test was implemented as the score test from the Cox model.) · Hazard ratio (hr): 1.005 · 95% CI 0.66 to 1.52Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate hazard ratios and corresponding confidence intervals for the pairwise comparisons of individual treatment arms with the trastuzumab alone arm.
SecondaryOverall Survival (OS) - Median Survival Follow-up

Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.

Time frame:
From randomization up to approximately year 10
Reported as:
Median · years
Overall Survival (OS) - Median Survival Follow-up
yearsLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
Overall Survival (OS) - Median Survival Follow-up9.70 (9.60 to 9.76)9.62 (8.86 to 9.67)9.64 (9.35 to 9.71)
SecondaryOverall Survival (OS) - Deaths and Censoring

Overall survival is defined as the period from randomization until death (from any cause). OS was assessed annually for up to 10 years after the randomization of the last participant into the study.

Time frame:
From randomization up to approximately year 10
Reported as:
Number · Number of Participants
Overall Survival (OS) - Deaths and Censoring
Number of ParticipantsLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
Number of deaths due to any cause263132
Number of subjects censored - total126123117
Number of subjects censored - Survival follow-up ongoing000
Number of subjects censored - Survival follow-up ended - total120121114
Number of subjects censored -Survival follow-up ended - Completed study follow-up745962
Number of subjects censored - Survival follow-up ended - Lost to follow-up222718
Number of subjects censored - Survival follow-up ended - Withdrew243534
Number of subjects censored - Other623
Statistical analysis
  • Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg vs Trastuzumab 2 mg/kg · Regression, Cox · p = 0.379 (The two-sided stratified log-rank test was implemented as the score test from the Cox model.) · Hazard ratio (hr): 0.788 · 95% CI 0.46 to 1.34Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate hazard ratios and corresponding confidence intervals for the pairwise comparisons of individual treatment arms with the trastuzumab alone arm.
  • Lapatinib 1500 mg vs Trastuzumab 2 mg/kg · Regression, Cox · p = 0.880 (The two-sided stratified log-rank test was implemented as the score test from the Cox model.) · Hazard ratio (hr): 0.962 · 95% CI 0.58 to 1.60Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate hazard ratios and corresponding confidence intervals for the pairwise comparisons of individual treatment arms with the trastuzumab alone arm.
SecondaryAssess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)

The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Clinical follow-up is the period during which the patient is monitored such that all recurrence or second primary malignancy (SPM) or contralateral breast cancer (CBC) events would be reported. Patients are considered in clinical follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death.

Time frame:
up to year 10
Reported as:
Median · years
Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)
yearsPathological Complete Response (pCR)No Pathological Complete Response (pCR)Overall
Median clinical follow-up - all subjects in the EFS landmark analysis9.05 (8.86 to 9.14)9.11 (9.05 to 9.14)9.09 (9.03 to 9.13)
Median clinical follow-up- EFS landmark analysis - lapatinib + trastuzumab arm (n=67,71,138)9.13 (8.97 to 9.23)9.10 (7.24 to 9.15)9.12 (8.97 to 9.15)
Median clinical follow-up - subjects in the EFS landmark analysis - lapatinib arm (n=30,104,134)8.08 (6.08 to 9.12)9.09 (8.52 to 9.19)9.05 (8.23 to 9.12)
Median clinical follow-up - subjects in the EFS landmark analysis - trastuzumab arm (n=39,99,138)8.98 (8.38 to 9.21)9.12 (9.03 to 9.25)9.11 (8.96 to 9.17)
Statistical analysis
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.00079 · Hazard ratio (hr): 0.481 · 95% CI 0.31 to 0.73Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.004 · Hazard ratio (hr): 0.350 · 95% CI 0.16 to 0.71Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.134 · Hazard ratio (hr): 0.532 · 95% CI 0.21 to 1.16Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.163 · Hazard ratio (hr): 0.601 · 95% CI 0.28 to 1.20Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
SecondaryAssess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)

The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. For patients who had breast cancer surgery, EFS events are post-surgery breast cancer relapse, second primary malignancy or death without recurrence. For patients who do not undergo breast cancer surgery, EFS events are death during clinical follow-up or non-completion of any neo-adjuvant investigational product due to disease progression or second primary malignancy or contralateral breast cancer.

Time frame:
up to year 10
Reported as:
Number · Number of participants
Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)
Number of participantsPathological Complete Response (pCR)No Pathological Complete Response (pCR)Overall
All subjects in the EFS landmark analysis with EFS events2998127
Subjects in the EFS landmark analysis - lapatinib + trastuzumab arm with EFS events (n=67,71,138)112839
Subjects in the EFS landmark analysis in the lapatinib arm with EFS events (n=30,104,134)73643
Subjects in the EFS landmark analysis in the trastuzumab arm with EFS events (n=39,99,138)113445
SecondaryAssess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)

The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Patients are considered in survival follow-up from randomisation until one of the following occurs: lost to follow-up, withdrawal of consent, end of follow-up due to completion of year 10 visit, termination of study follow-up, or death. For subjects with no death recorded in the database, time to death is censored.

Time frame:
up to year 10
Reported as:
Median · years
Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)
yearsPathological Complete Response (pCR)No Pathological Complete Response (pCR)Overall
Median survival follow-up - All subjects in the OS landmark analysis9.10 (8.97 to 9.18)9.09 (9.03 to 9.12)9.09 (9.04 to 9.13)
Median survival follow-up - OS landmark analysis in the lapatinib + trastuzumab arm (n=67,72,139)9.14 (9.05 to 9.24)9.09 (7.95 to 9.15)9.12 (9.05 to 9.16)
Median survival follow-up - OS landmark analysis in the lapatinib (n=30,109,139)8.31 (7.24 to 9.15)9.08 (8.95 to 9.14)9.07 (8.50 to 9.12)
Median survival follow-up - OS landmark analysis in the trastuzumab arm (n=40,102,142)8.98 (8.02 to 9.21)9.09 (8.51 to 9.15)9.07 (8.86 to 9.14)
Statistical analysis
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.00041 · Hazard ratio (hr): 0.366 · 95% CI 0.20 to 0.63Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.002 · Hazard ratio (hr): 0.223 · 95% CI 0.07 to 0.58Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.125 · Hazard ratio (hr): 0.433 · 95% CI 0.12 to 1.17Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
  • Pathological Complete Response (pCR) vs No Pathological Complete Response (pCR) · Regression, Cox · p = 0.058 · Hazard ratio (hr): 0.414 · 95% CI 0.15 to 1.00Cox models (Cox, 1972), with the stratification factors entered as strata variables, were used to calculate a hazard ratio and corresponding confidence interval comparing pCR and no pCR.
SecondaryAssess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)

The landmark date is 30 weeks after a subject's randomization. Subjects with missing pCR status were not included in the landmark analysis. Includes deaths due to any cause.

Time frame:
up to year 10
Reported as:
Number · Number of Participants
Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)
Number of ParticipantsPathological Complete Response (pCR)No Pathological Complete Response (pCR)Overall
All participants in the OS landmark analysis who died157085
Participants in the OS landmark analysis in the lapatinib + trastuzumab arm who died (n=67,72,139)51924
Participants in the OS landmark analysis in the lapatinib arm who died (n=30,109,139)42630
Participants in the OS landmark analysis in the trastuzumab arm who died (n=40,102,142)62531
SecondaryTo Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints
Time frame:
Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 31 weeks.
Reported as:
Count of participants · Participants
To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints
ParticipantsLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints2 (0.16 to 4.76)0 (0.00 to 2.41)1 (0.02 to 3.71)
SecondaryMetabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)

Metabolic Response Rate determined by Positron Emission Tomography/Computed Tomography (PET/CT)

Time frame:
Week 2 and Week 6
Reported as:
Number · Percentage of participants
Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)
Percentage of participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Metabolic Response Rate (%) Determined by PET/CT at week 266.756.595.0
Metabolic Response Rate (%) Determined by PET/CT at week 660.943.578.9
SecondaryPercentage of Participants With the Indicated Biomarker Expression - PIK3CA.

Biomarker levels of phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) were assessed in participants at baseline.

Time frame:
Baseline
Reported as:
Number · Percentage of participants
Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.
Percentage of participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.231925
SecondaryPercentage of Participants With the Indicated Biomarker Expression - PTEN.

Biomarker levels of phosphate and tensin homolog deleted from chromosome 10 (PTEN) were assessed in participants at baseline.

Time frame:
Baseline
Reported as:
Number · Percentage of participants
Percentage of Participants With the Indicated Biomarker Expression - PTEN.
Percentage of participantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Biomarker: PTEN by Cell Signalling Technology - PTEN Normal (%)747075
Biomarker: PTEN by Cell Signalling Technology - PTEN Loss (%)263025
SecondaryRatio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR

Ratio (95% CI) of geometric means in p95 human epidermal growth factor receptor (p95HER2) expression in hormone-receptor (HR) positive patients with pathological complete response (pCR) vs no pCR

Time frame:
Baseline
Reported as:
Geometric mean · Ratio
Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR
RatioLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR1.0 (0.50 to 1.87)1.6 (1.0 to 2.71)2.1 (1.2 to 3.7)
SecondaryPercentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream

Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. In the adjuvant phase, after surgery all participants received 3 courses of adjuvant 5-fluorouracil, epirubicin and cyclophosphamide, followed by lapatinib 1500 mg or trastuzumab 2 mg/kg or lapatinib 1000/750 mg plus trastuzumab 2 mg/kg given prior to surgery in the neoadjuvant setting for an additional 34 weeks.

Time frame:
Measurement performed at one or more of the time points: baseline, week 2 or week 18
Reported as:
Number · Percentage of Participants
Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream
Percentage of ParticipantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream211725
Post-hocAll Collected Deaths

On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, which was approximately 31 weeks. Deaths post treatment survival follow up were collected after the on treatment period, up to 10 years.

Time frame:
on-treatment: up to week 31; post-treatment: up to year 10
Reported as:
Number · Participants
All Collected Deaths
ParticipantsLapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kg
Total Deaths313226
On-Treatment Deaths (n=151,148,149)201

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 31 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg1/149 (0.7%)61/149 (40.9%)147/149 (98.7%)
Lapatinib 1500 mg2/151 (1.3%)58/151 (38.4%)148/151 (98%)
Trastuzumab 2 mg/kg0/148 (0%)36/148 (24.3%)141/148 (95.3%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
HYPERTRANSAMINASAEMIAHepatobiliary disorders15/14923/1513/148
NEUTROPENIABlood and lymphatic system disorders14/14913/15116/148
DIARRHOEAGastrointestinal disorders9/1499/1510/148
FEBRILE NEUTROPENIABlood and lymphatic system disorders3/1492/1518/148
PYREXIAGeneral disorders5/1492/1512/148
HYPERBILIRUBINAEMIAHepatobiliary disorders4/1494/1510/148
CARDIAC FAILURE CONGESTIVECardiac disorders3/1490/1511/148
VOMITINGGastrointestinal disorders3/1491/1512/148
URINARY TRACT INFECTIONInfections and infestations0/1493/1510/148
CELLULITISInfections and infestations2/1491/1512/148
Most frequent other events
Showing 10 of 178
Most frequent other events
EventLapatinib 1000/750 mg + Trastuzumab 2 mg/kgLapatinib 1500 mgTrastuzumab 2 mg/kg
DIARRHOEAGastrointestinal disorders128/149123/15152/148
ALOPECIASkin and subcutaneous tissue disorders95/14990/15196/148
NAUSEAGastrointestinal disorders75/14981/15176/148
RASHSkin and subcutaneous tissue disorders67/14968/15128/148
VOMITINGGastrointestinal disorders54/14957/15138/148
HYPERTRANSAMINASAEMIAHepatobiliary disorders55/14955/15139/148
FATIGUEGeneral disorders52/14945/15138/148
NEUTROPENIABlood and lymphatic system disorders47/14951/15137/148
ASTHENIAGeneral disorders39/14947/15135/148
DECREASED APPETITEMetabolism and nutrition disorders35/14939/15117/148

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
Median50.0 (28 to 79)49.0 (23 to 77)50.0 (25 to 80)50.0 (23 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
Female154149152455
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
American Indian or Alaska Native13141542
Asian - Central/South75517
Asian - East30283189
Asian - South East0022
Black or African American/African Heritage0448
White - Arabic/North African Heritage65314
White - Caucasian European Heritage979392282
Missing1001
Number of participants with tumor cells of the indicated histologic grade
Number of participants with tumor cells of the indicated histologic grade(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
Well differentiated25512
Moderately differentiated565363172
Poorly differentiated736864205
Differentiation cannot be assessed22232065
Missing1001
Number of participants with lymph nodes (LNs) of the indicated clinical N stage
Number of participants with lymph nodes (LNs) of the indicated clinical N stage(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
N0344148123
N1958580260
N2 (including N2a and N2b)19131547
N3 (including N3a, N3b, and N3c)67619
Nx0336
Number of participants with the indicated IHC results
Number of participants with the indicated IHC results(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
Not applicable605361174
Equivocal: Score of 2+95822
Positive: Score of 3+818976246
Negative: Score of 0-1+0134
Non interpretable4149
Number of participants with the indicated FISH results
Number of participants with the indicated FISH results(Participants)Lapatinib 1500 mgTrastuzumab 2 mg/kgLapatinib 1000/750 mg + Trastuzumab 2 mg/kgTotal
Not applicable384241121
Amplified115105109329
Not amplified1214
Not interpretable0011
08

Study locations

122 sites
  • Novartis Investigative Site
    Berazategui, Buenos Aires B1880BBF, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1125ABD, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1185AAT, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000KZE, Argentina
  • Novartis Investigative Site
    Quilmes, 1878, Argentina
  • Novartis Investigative Site
    Santa Fe, 3000, Argentina
  • Novartis Investigative Site
    Tucuman, 4000, Argentina
  • Novartis Investigative Site
    Brussels, 1000, Belgium
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Namur, 5000, Belgium
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90430-090, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90560-030, Brazil
  • Novartis Investigative Site
    Santo Andre, São Paulo 09060-650, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 03102-002, Brazil
  • Novartis Investigative Site
    Montreal, Quebec H4J 1C5, Canada
  • Novartis Investigative Site
    Brno, 656 53, Czechia
  • Novartis Investigative Site
    Novy Jicin, 741 01, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    Bayonne, 64100, France
  • Novartis Investigative Site
    Bordeaux, 33077, France
  • Novartis Investigative Site
    Le Mans, 72015, France
  • Novartis Investigative Site
    Levallois-Perret, 92300, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Strasbourg, 67085, France
  • Novartis Investigative Site
    Toulouse, 31076, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • Novartis Investigative Site
    Karlsruhe, Baden-Wuerttemberg 76135, Germany
  • Novartis Investigative Site
    Fuerth, Bayern 90766, Germany
  • Novartis Investigative Site
    Nuernberg, Bayern 90340, Germany
  • Novartis Investigative Site
    Fuerstenwalde, Brandenburg 15517, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hessen 60590, Germany
  • Novartis Investigative Site
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • Novartis Investigative Site
    Stralsund, Mecklenburg-Vorpommern 18435, Germany
  • Novartis Investigative Site
    Celle, Niedersachsen 29223, Germany
  • Novartis Investigative Site
    Hannover, Niedersachsen 30625, Germany
  • Novartis Investigative Site
    Dortmund, Nordrhein-Westfalen 44137, Germany
  • Novartis Investigative Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • Novartis Investigative Site
    Koeln, Nordrhein-Westfalen 50937, Germany
  • Novartis Investigative Site
    Witten, Nordrhein-Westfalen 58452, Germany
  • Novartis Investigative Site
    Halle, Sachsen-Anhalt 06120, Germany
  • Novartis Investigative Site
    Kiel, Schleswig-Holstein 24105, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13589, Germany
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Kowloon, Hong Kong
  • Novartis Investigative Site
    Wanchai, Hong Kong
  • Novartis Investigative Site
    Budapest, H-1122, Hungary
  • Novartis Investigative Site
    Bangalore, 560029, India
  • Novartis Investigative Site
    Hyderabad, 500082, India
  • Novartis Investigative Site
    Mumbai, 400012, India
  • Novartis Investigative Site
    Nagpur, 440010, India
  • Novartis Investigative Site
    New Delhi, 110060, India
  • Novartis Investigative Site
    New Delhi, 110076, India
  • Novartis Investigative Site
    Pune, 411001, India
  • Novartis Investigative Site
    Roma, Lazio 00144, Italy
  • Novartis Investigative Site
    Genova, Liguria 16132, Italy
  • Novartis Investigative Site
    Lecco, Lombardia 23900, Italy
  • Novartis Investigative Site
    Milano, Lombardia 20132, Italy
  • Novartis Investigative Site
    Milano, Lombardia 20141, Italy
  • Novartis Investigative Site
    Monza, Lombardia 20052, Italy
  • Novartis Investigative Site
    Sondrio, Lombardia 23100, Italy
  • Novartis Investigative Site
    Trento, Trentino-Alto Adige 38100, Italy
  • Novartis Investigative Site
    Seoul, 003722, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138-736, Korea, Republic of
  • Novartis Investigative Site
    Songpa-gu, Seoul, 138-736, Korea, Republic of
  • Novartis Investigative Site
    Vilnius, LT-08660, Lithuania
  • Novartis Investigative Site
    Oslo, 0310, Norway
  • Novartis Investigative Site
    Oslo, 0407, Norway
  • Novartis Investigative Site
    Karachi, 74800, Pakistan
  • Novartis Investigative Site
    Lima, Lima 11, Peru
  • Novartis Investigative Site
    Lima, Lima 34, Peru
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Bucharest, 050098, Romania
  • Novartis Investigative Site
    Bucuresti, 022328, Romania
  • Novartis Investigative Site
    Cluj-Napoca, 400015, Romania
  • Novartis Investigative Site
    Moscow, 115 478, Russian Federation
  • Novartis Investigative Site
    Ryazan, 390011, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197758, Russian Federation
  • Novartis Investigative Site
    Pretoria, Gauteng 0181, South Africa
  • Novartis Investigative Site
    Athlone Park, Amanzimtoti, 4126, South Africa
  • Novartis Investigative Site
    Capital Park, 0002, South Africa
  • Novartis Investigative Site
    Parktown, 2193, South Africa
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Girona, 17007, Spain
  • Novartis Investigative Site
    Lerida, 25198, Spain
  • Novartis Investigative Site
    Madrid, 28033, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Mataro, 08304, Spain
  • Novartis Investigative Site
    Santiago de Compostela, 15706, Spain
  • Novartis Investigative Site
    Sevilla, 41013, Spain
  • Novartis Investigative Site
    Toledo, 45004, Spain

Showing the first 100 of 122 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Baselga J, Piccart M, Gelber R, di CosimoS, Viale G, Koehler M, Rojo F. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study [BIG 1-06 /solti/EGF106903]: a phase III translational study for HER2-overexpressing early breast cancer. [Lancet]. 2012;S140-6736(11):
  • Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, Brauer HA, Warren S, Danaher P, Colon-Otero G, Partridge AH, Carey LA, Hilbers F, Van Dooren V, Holmes E, Di Cosimo S, Werner O, Huober JB, Dueck AC, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson KL, Perez EA, Thompson EA. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24;8(1):68. doi: 10.1038/s41523-022-00430-0. PubMed 35610260 ↗
  • Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Med. 2022 Jan;11(2):332-339. doi: 10.1002/cam4.4449. Epub 2021 Dec 17. PubMed 34921525 ↗
  • Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2018 Nov 1;4(11):e181564. doi: 10.1001/jamaoncol.2018.1564. Epub 2018 Nov 8. PubMed 29902299 ↗
  • Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothe F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2017 Feb 1;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824. Erratum In: JAMA Oncol. 2019 Jan 1;5(1):122. doi: 10.1001/jamaoncol.2018.5678. PubMed 27684533 ↗
  • Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015 Jul;1(4):448-54. doi: 10.1001/jamaoncol.2015.0830. Erratum In: JAMA Oncol. 2015 Jul;1(4):544. doi: 10.1001/jamaoncol.2015.1805. JAMA Oncol. 2015 Nov;1(8):1172. doi: 10.1001/jamaoncol.2015.4229.. Nucifero, Paolo [corrected to Nuciforo, Paolo]. JAMA Oncol. 2019 Jan 1;5(1):122. doi: 10.1001/jamaoncol.2018.5678. PubMed 26181252 ↗
  • Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Pena L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol. 2015 Jul;26(7):1494-500. doi: 10.1093/annonc/mdv175. Epub 2015 Apr 7. PubMed 25851628 ↗
  • de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. doi: 10.1016/S1470-2045(14)70320-1. Epub 2014 Aug 14. PubMed 25130998 ↗
  • Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309. PubMed 22785351 ↗
  • Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Erratum In: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. PubMed 22257673 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in May 2010, 28 months.

Results were first posted in Oct 2011, 1 year 4 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2007
First posted
Nov 4, 2007
StartActual
Jan 5, 2008
Primary completionActual
May 27, 2010
CompletionActual
Dec 23, 2019
Results first posted
Oct 13, 2011
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00553358
Collaborators
Breast International Group, SOLTI Breast Cancer Research Group
Responsible party
Sponsor
First posted
Nov 4, 2007
Start date
Jan 5, 2008
Primary completion
May 27, 2010
Completion
Dec 23, 2019
Results posted
Oct 13, 2011
Last update
Sep 21, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Trastuzumab

Start the discussion